Neoadjuvant and adjuvant therapy combined with resection of hepatic colorectal cancer metastases

Liver-only metastases occur in approximately one third of patients with metastatic colorectal cancer. Surgery is possible in portion of patients and remains the only potentially curative procedure. The use of neoadjuvant therapy may enhance the portion of patients that may be considered for surgery. For patients with initially resectable liver-only metastases, adjuvant therapy has been shown to be of benefit when combined with liver-directed therapy. Adjuvant therapy can reduce the rate of recurrence and extend survival.